Aardvark Therapeutics, Inc. AARD
0.91 USD -0.24 (-20.87%)
Regular-session close
0.94 +0.03 +3.16%
After hours · Nov 18, 4:35 PM ET
0.9062 Day range 1.21
0.9062 52-week range 16.60
- YTD
- -93.07%
- 1 year
- -90.75%
News
globenewswire.com Aardvark Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates FDA lifted clinical hold on ARD-101 for the treatment of hyperphagia in Prader-Willi Syndrome (PWS) Meeting with the FDA scheduled for the first quarter of 2027 to discuss the Company's proposed…benzinga.com Aardvark Therapeutics Q3 EPS $(0.88) Misses $(0.77) Estimate Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.88) per share which missed the analyst consensus estimate of $(0.77) by 14.29 percent. This is a 17.33 percent decrease over…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) shares rose 23.1% to $89.86 during Tuesday's regular session. The market value of their outstanding shares is at $5.6 billion. As per the press release,…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Surgery Partners (NASDAQ:SGRY) shares moved upwards by 46.9% to $23.14 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. SciSparc (NASDAQ:SPRC)…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers SciSparc (NASDAQ:SPRC) shares moved upwards by 39.4% to $1.52 during Monday's pre-market session. Xencor (NASDAQ:XNCR) stock moved upwards by 29.46% to $32.6. The company's market cap stands…benzinga.com HC Wainwright & Co. Maintains Neutral on Aardvark Therapeutics, Lowers Price Target to $2 HC Wainwright & Co. analyst Raghuram Selvaraju maintains Aardvark Therapeutics (NASDAQ:AARD) with a Neutral and lowers the price target from $4 to $2.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Bolt Biotherapeutics (NASDAQ:BOLT) shares moved upwards by 58.8% to $6.65 during Friday's regular session. The market value of their outstanding shares is at $7.9 million. Lucid Diagnostics…
benzinga.com Aardvark Therapeutics Says Current Prader-Willi Syndrome Drug Data Insufficient Aardvark Therapeutics reports Phase 3 data for ARD-101 and prepares to meet with the FDA to discuss lower-dose testing.
benzinga.com Dow Tumbles Over 500 Points; American Express Shares Fall After Q3 Results U.S. stocks fell Friday, led by a 500-point Dow drop. Industrials slid while real estate rose; AmEx fell despite an earnings beat. Oil gained 2%.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 29.7% to $0.42 during Friday's pre-market session. The company's market cap stands at $63.6 million. Electra Therapeutics (NASDAQ:ETRA)…benzinga.com Aardvark Therapeutics Reports Exploratory Phase 3 HERO And OLE Data Showing Rapid Hunger Score Reductions With ARD-101 In PWS, FDA Lifts Clinical Hold And Company Targets New Phase 3 Trial HERO trial terminated early (67 of 90 planned participants randomized); all efficacy data are considered exploratoryHQ-CT scores fell by Week 2 of dose escalation on ARD-101 and returned to near…
benzinga.com Why RingCentral Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket RingCentral surged 15% after beating Q3 estimates and raising FY26 guidance; XXII, LABT and HUBC led premarket gainers, while LNAI fell.
benzinga.com Aardvark Therapeutics Stock Surges as FDA Lifts Clinical Hold After Cardiac Safety Concerns Aardvark Therapeutics shares jumped 25.06% after hours as the FDA lifted its clinical hold on ARD-101 development.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 41.9% to $0.46 during Thursday's after-market session. The company's market cap stands at $67.1 million. Aardvark Therapeutics…benzinga.com FDA Removes Clinical Hold From Aardvark Therapeutics' Investigational New Drug Application For ARD-101 To Treat Hyperphagia In Prader-Willi Syndrome Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the…
benzinga.com HC Wainwright & Co. Maintains Neutral on Aardvark Therapeutics, Lowers Price Target to $4 HC Wainwright & Co. analyst Raghuram Selvaraju maintains Aardvark Therapeutics (NASDAQ:AARD) with a Neutral and lowers the price target from $6 to $4.
